Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant...
-
Upload
reginald-malone -
Category
Documents
-
view
219 -
download
1
Transcript of Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant...
![Page 1: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/1.jpg)
Systemic Lupus Erythematosus
Mohammed A. Omair MBBS, SF RheumConsultant Rheumatologist
Assistant ProfessorProgram Director of the KSU Rheumatology
FellowshipKing Khalid University Hospital
King Saud University
![Page 2: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/2.jpg)
Objectives
• Introduction• Pathogenesis• When to diagnose SLE and the use of the
classification criteria• Auto-antibodies and complement• Important organ involvement• Therapies• Disease related complications• Drug related complications
![Page 3: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/3.jpg)
Introduction
• SLE is a chronic autoimmune disease that affects almost all body organs.
• The pathogenesis rely heavily on autoantibody production and the formation of immune complexes that deposit into the tissue consequently leading to complement activation and damage.
• The story starts when you lose self tolerance due to defective clearance.
![Page 4: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/4.jpg)
Genetic Background
Mok, C. and Lau, C.J Clin Pathol. 2003 Jul; 56(7): 481–490.
![Page 5: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/5.jpg)
Environmental Trigger
Mok, C. and Lau, C.J Clin Pathol. 2003 Jul; 56(7): 481–490.
![Page 6: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/6.jpg)
Immune System Dysregulation
Mok, C. and Lau, C.J Clin Pathol. 2003 Jul; 56(7): 481–490.
![Page 7: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/7.jpg)
Pathogenesis of SLE
Mok, C. and Lau, C.J Clin Pathol. 2003 Jul; 56(7): 481–490.
![Page 8: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/8.jpg)
1997 Modified ACR CriteriaCriterion Definition
1. Malar Rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the nasolabial folds
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular plugging; atrophic scarring may occur in older lesions
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or physician observation
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician
5. Nonerosive Arthritis Involving 2 or more peripheral joints, characterized by tenderness, swelling, or effusion
6. Pleuritis or Pericarditis 1.Pleuritis--convincing history of pleuritic pain or rubbing heard by a physician or evidence of pleural effusion2.OR2.Pericarditis--documented by electrocardigram or rub or evidence of pericardial effusion
7. Renal Disorder 1.Persistent proteinuria > 0.5 grams per day or > than 3+ if quantitation not performed2.OR2.Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed
8. Neurologic Disorder 1.Seizures--in the absence of offending drugs or known metabolic derangements; e.g., uremia, ketoacidosis, or electrolyte imbalance2.OR2.Psychosis--in the absence of offending drugs or known metabolic derangements, e.g., uremia, ketoacidosis, or electrolyte imbalance
9. Hematologic Disorder 1.Hemolytic anemia--with reticulocytosis2.OR2.Leukopenia--< 4,000/mm3 on ≥ 2 occasions3.OR3.Lyphopenia--< 1,500/ mm3 on ≥ 2 occasions4.OR4.Thrombocytopenia--<100,000/ mm3 in the absence of offending drugs
10. Immunologic Disorder 1.Anti-DNA: antibody to native DNA in abnormal titer2.OR2.Anti-Sm: presence of antibody to Sm nuclear antigen3.OR3.Positive finding of antiphospholipid antibodies on:4.1. an abnormal serum level of IgG or IgM anticardiolipin antibodies,5.2. a positive test result for lupus anticoagulant using a standard method, or6.3. a false-positive test result for at least 6 months confirmed by Treponema pallidum immobilization or fluorescent treponemal antibody absorption test
11. Positive Antinuclear Antibody
An abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay at any point in time and in the absence of drugs
![Page 9: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/9.jpg)
2012 SLICC Criteria
![Page 10: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/10.jpg)
What to do When Your Patient Does Not Fit?
• Definitive• Probable (useless)• Possible (useless)• When you are not sure call it
undifferentiated connective disease!!!
![Page 11: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/11.jpg)
Autoantibodies
• There are more than 100 identified autoantibody for SLE.
• Their presence is not only important for diagnosis but some of them can predict organ involvement.
![Page 12: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/12.jpg)
ANA• Present in more than 95% of subjects.• ANA negative lupus does not exist in the mind
of some rheumatologists.• If present it should exclusively diagnosed by an
experienced rheumatologist.• A titer ≥ 1:160 can be considered positive.• Remember only 11-13% of persons with a
positive ANA test have lupus and up to 15% of completely healthy people have a positive ANA test (up to 37% in people older than 65 years).
![Page 13: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/13.jpg)
Anti-Double Stranded DNA
• Anti-dsDNA antibodies are highly specific to SLE: < 0.5 % of healthy people or patients with other autoimmune diseases have anti-dsDNA antibodies, whereas 70 % of SLE patients are positive.
Isenberg DA, et al. Arthr Rheum. 1985; 28(9):999–1007.
![Page 14: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/14.jpg)
Anti-Double Stranded DNA
• Can be detected in the serum of patients before the onset of the disease.
• Correlates well with disease activity.• Decreases with therapy.• It is highly associated with renal
involvement
![Page 15: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/15.jpg)
Anti-Smith (Sm)
• The sensitivity and specifity of anti-Sm are 39.7% and 98.6%, respectively.
• Can be present before the onset of SLE.
• Does not change with disease activity.
Pan, L. Et al. Ann Acad Med Singapore.1998 Jan;27(1):21-3.
![Page 16: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/16.jpg)
Anti-Ro and Anti-La
• Anti-Ro/SSA and anti-La/SSB antibodies are present in approximately 30 and 20 percent of patients with SLE, respectively.
• Their presence signifies:- Overlap with Sjogren’s syndrome- Risk of cutaneous lupus- Risk of CHB in pregnant mamas with
lupus.- ANA negative lupus!!!
![Page 17: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/17.jpg)
Complement• The complement system is a humoral
component of the innate immune system that contains about 30 proteins.
• Complement becomes activated by 3 main pathways: the classical, alternative, and lectin pathways.
• All 3 pathways converge on the generation of C3 convertases that result in the production of anaphylatoxins and a proinflammatory cascade.
![Page 18: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/18.jpg)
Pathways in Complement Activation
![Page 19: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/19.jpg)
Complement in SLE
• Deficiencies (of early components C1q, C4) predispose to pediatric SLE.
• Activation leads to deposition and organ damage.
• Levels decrease with activity and improve with treatment.
![Page 20: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/20.jpg)
How to Approach a Patient with SLE
• Ask every single question in Nicholas Talley.
• It is called the disease with a 1000 faces.• Make sure you look for an overlap
(Sjogren’s syndrome, APS, SSc, RA, DM).• Higher prevalence of other autoimmune
diseases (hypothyroidism, celiac disease, and vitiligo).
![Page 21: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/21.jpg)
Hematological Manifestations
• One or more cell line• leucopenia• Anemia• Thrombocytopenia• TTP• Pure red cell aplasia
![Page 22: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/22.jpg)
Treatment
• Steroids• Azathioprine• MMF• RTX• Splenectomy• TPE for TTP
![Page 23: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/23.jpg)
REMEMBER INFECTION AND DRUG INDUCED
BONE MARROW SUPPRESSION
![Page 24: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/24.jpg)
SEROSITIS
• Usually steroid responsive but in some patients needs a steroid sparing agent.
![Page 25: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/25.jpg)
Renal Involvement
• The most common internal organ involvement affecting up to 75% of patients in their lifetime.
• Can be part of the first presentation • Clinical Presentation:- Asymptomatic proteinuria- New onset HTN- Nephrotic syndrome- Rapidly Progressive Glomerulonephritis
![Page 26: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/26.jpg)
Renal Involvement
• Glomerular disease (LN)• Tubulointerstitial nephritis• TTP• APS related with • Overlap with AAV
![Page 27: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/27.jpg)
Lupus Nephritis
• The ISN classification system divides glomerular disorders associated with SLE into 6 different patterns:
- Minimal mesangial lupus nephritis (class I) - Mesangial proliferative lupus nephritis (class
II) - Focal lupus nephritis (class III)- Diffuse IV lupus nephritis (class IV)- Membranous lupus nephritis (class V)- Advanced sclerosing lupus nephritis (class VI)
![Page 28: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/28.jpg)
Investigation
• Creatinine• Urinalysis • 24 hour protein • US kidney• Kidney biopsy • Indications: elevated serum creatinine,
24 hour excretion more > 500 mg/day or active urine sediment.
![Page 29: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/29.jpg)
Treatment• Class I: no specific treatment (rarely seen)• Class II: no specific directed therapy (maybe
increasing corticosteroids and optimizing the immunosuppressive agent)
• Class III & IV: Induction (CYC or MMF+ high dose corticosteroids) maintenance (AZA or MMF) (RTX as 3rd line for either induction or maintenance)
• Class V: same as proliferative but CsA and tacrolimus may play a role.
• Class VI: prepare for dialysis or evaluate for transplant.
![Page 30: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/30.jpg)
REMEMBER TO ALWAYS LOOK AT THE MSU OF A
LUPUS PATIENT
![Page 31: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/31.jpg)
Neuropsychiatric Involvement
• Neurologic and psychiatric symptoms occur in 10-80% of patients.
• The pathogenesis can involve one or more of the following:
- Vasculopathy- Autoantibodies (Ribosomal P antibody, anti-
neuronal antibodies)- Other: These include cytokines,
neuropeptides, oxidative stress, nitric oxide , and interference with neurotransmission
![Page 32: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/32.jpg)
Clinical manifestations
• Cognitive dysfunction.• Headache.• Mood disorder.• Cerebrovascular disease.• Seizures.• Polyneuropathy.• Anxiety.• Psychosis
![Page 33: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/33.jpg)
Imaging
• Brain atrophy disproportioned to age is common.
• Demyelination• Small vessel disease or Stroke• Normal MRI with active lupus
cerebritis
![Page 34: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/34.jpg)
Treatment• Steroids and CYC for inflammatory
complications.• Alternatives could be RTX, CsA, and FK506• ASA and/or warfarin for stroke syndromes
(always check for APS)• Anti-epileptic for seizures• Pain modulating drugs for neuropathy.• Headache treat the underlying cause
![Page 35: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/35.jpg)
REMEMBER CNS INFECTION IS NOT TO BE
MISSED
![Page 36: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/36.jpg)
Skin
• Skin is commonly involved in SLE.• There are more than 20 types of
rashes in lupus.• In a culture like ours many women
live with many of these complications in silence.
• It is our job to improve detection and management of these lesions.
![Page 37: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/37.jpg)
Photosensitive Rashes• Butterfly and all others can be easily
managed by a very novel and advanced strategy called PREVENTION
• HCQ plays a major role in the treatment of cutaneous lupus.
• Systemic steroids, azathioprine, dapsone.
• Topical cream is not our business.
![Page 38: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/38.jpg)
Discoid Rash• Can be the sole cutaneous manifestation.• The risk of progression to SLE in patients
with DLE was demonstrated to be 16.7% progression within 3 years of diagnosis.
• Classically presents with erythematous-to violaceous, scaly plaques with prominent follicular plugging that often results in scarring and atrophy.
![Page 39: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/39.jpg)
Other Rashes
• RP with gangrene• Purpuric rash• Pemphigoid• Psoriaform
![Page 40: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/40.jpg)
REMEMBER WHEN YOU ARE NOT SURE REQUEST A
SKIN BIOPSY
![Page 41: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/41.jpg)
Hydroxychloroquine• Standard of care in every SLE patient.• Has a positive effect on: proteinuria,
cutaneous, arthritis, thrombotic events, hyperlipidema, hyperglycemia, and improves survival.
• Dose is 6.3mg/kg.• Adverse events: GIT, myopathy, and
retinopathy.
![Page 42: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/42.jpg)
REMEMBER TO SEND THEM FOR ANNUAL
SCREENING FOR RETINAL TOXICITY
![Page 43: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/43.jpg)
Azathioprine
• Steroid sparing agent• Effective as maintenance of LN,
myositis, cutaneous lupus, CNS lupus.• Dose is 2-3mg/kg• Adverse events: hypersensitivity
reaction, pancytopenia, and hepatitis• Thiopurine methyltransferase or
thiopurine S-methyltransferase (TPMT) can predict AEs
![Page 44: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/44.jpg)
Mycophenolate Mofetil
• Mainly used as induction and maintenance of LN.
• Can be used for myositis, cutaneous or CNS lupus.
• Dose is 2-3g/day• Adverse events: GIT, and
pancytopenia.
![Page 45: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/45.jpg)
CsA and Tacrolimus• Used mainly in LN class V.• Maybe used for CNS lupus.• Low dose CsA can be effective in SLE
3mg/kg/day• Tacrolimus dose is 2-3mg/day• Drug level guides the dosing • Adverse events: HTN, ginigival
hyperplasia, hypertrichosis, DM, and increase creatinine.
![Page 46: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/46.jpg)
Rituximab
• Almost used in everything• Dose can be calculated with the
lymphoma protocol or RA protocol.• Despite it failed the RCTs its efficacy
is unshakable in the heads of rheumatologists.
• Adverse events: hypersensitivity reaction, fluid retention, and PML.
![Page 47: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/47.jpg)
Belimumab
• Anti-BLyS (B-cell stimulating factor inhibitor).
• The first and only biologic approved for SLE.
• Approved for seropositive SLE with refractory mucocutaneus and articular manifestations.
![Page 48: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/48.jpg)
Disease Related Complications
• There have been a major improvement in the outcome of SLE over the last 30 years.
• Still a minority die from DAH, RPGN, PHTN, and myocarditis.
![Page 49: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/49.jpg)
Treatment Related Complications• Now living longer we discovered that if
management is not done systematically (liberally).
• Patients develop steroids related complications and die from premature CAD.
• If immunosuppressive medications are not tapered when disease is quiescent patients die from infections and drug side effect.
• Risk of malignancy is higher in SLE.
![Page 50: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/50.jpg)
REMEMBER YOU CAN HARM MORE THAN DO
GOOD IF YOU DO NOT RE-EVALUATE YOUR PATIENTS’ NEEDS
![Page 51: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/51.jpg)
REMEMBER YOU ARE TREATING A HUMAN WITH
LUPUS!DISCUSS VACCINATION, FERTILITY, CONCEPTION, METABOLIC SYNDROME
AND CANCER SCREENING
![Page 52: Systemic Lupus Erythematosus Mohammed A. Omair MBBS, SF Rheum Consultant Rheumatologist Assistant Professor Program Director of the KSU Rheumatology Fellowship.](https://reader035.fdocuments.in/reader035/viewer/2022062517/56649f2b5503460f94c45683/html5/thumbnails/52.jpg)
THANK YOU!!!